the patency of dialysis grafts, 5, 13, 42 pulmonary arteries, 17, 27 the superior vena cava, 15 intracerebral arteries, 3, 10 and dural sinuses. 2 This paper presents a successful multimodality endovascular approach to cerebral venous thrombosis by using endovascular fibrinolytic agents, superselective deep cerebral vein catheterization, and/or mechanical clot maceration in symptomatic patients.
Clinical Material and Methods
Six patients (two male and four female) aged 14 to 75 years (mean 33 years) presented with progressive symptoms from cerebral venous thrombosis (Table 1 ). All had risk factors for venous thrombosis, including inflammatory bowel disease (two patients), nephrotic syndrome (one), cancer (one), childbirth (one), and oral contraceptive use (one). Five presented with progressive neurological deficits, including visual acuity changes (one patient), hemiparesis (three), and altered mental status (two), and one patient had a progressive and intractable headache. Three patients presented with a Glasgow Coma Scale 38 (GCS) score of 15, whereas the remaining three presented with scores of 7, 14, and 5, respectively (median 10). After confirmation of intracranial venous thrombosis on CT scanning, MR imaging, and MR venography, all patients were started on intravenously administered heparin as part of their preendovascular procedure therapy.
Patients underwent diagnostic cerebral arteriography followed by transvenous catheterization and selective sinus and deep venous microcatheterization. All patients underwent right femoral vein and ipsilateral femoral artery catheterization (in which single-walled and doublewalled puncture techniques, respectively, were used) followed by heparin therapy after access was established. A late venous phase cerebral arteriogram was obtained. On the venous side, a microcatheter (Tracker-18; Target Therapeutics, Fremont, CA) was advanced through a catheter (No. 7 French Berenstein; Bard, Billerica, MA) and placed at the level of the right sigmoid sinus.
Once the extent of cerebral venous thrombosis was established, the microcatheter was advanced, and selectively maneuvered into the appropriate dural venous sinuses and/or deep venous structures, paying special attention to manipulation of the devices in venous structures more predisposed to catheter penetration. No catheters other than those mentioned previously and those in standard use for arterial catheterization were utilized for superselective catheterization of the venous structures. Advancement of the microcatheter through the clot was followed by the delivery of approximately 50,000 IU of urokinase every 15 minutes at the cephalad aspect of the thrombus by using the pulse-spray technique. If there was no change in the venographic appearance of the thrombus after delivery of approximately 200,000 IU of urokinase, mechanical disruption of the thrombus was performed by dragging a microsnare (Amplatz Goose Neck microsnare; Microvena, White Bear Lake, MN, Fig. 1 ) repeatedly over the thrombus surface. After clot maceration, urokinase infusion was reinitiated and continued until venous patency or a total dosage of 1,000,000 IU of urokinase was reached. Angiographic studies performed at the conclusion of the thrombolytic procedure allowed us to de-termined sinus/venous patency and the arteriovenous relationship, especially with regard to transit time. The femoral sheaths were maintained for 24 hours after the procedure, and the patients continued to receive systemic anticoagulation therapy with intravenously administered heparin.
Four patients suffered combined dural and deep thrombosis, whereas clot formation was limited to the dural venous sinuses in two patients. In the four patients with deep cerebral thrombosis, clots were noted in the internal cerebral veins (three vessels), straight sinus (three), vein of Galen (one), and inferior sagittal sinus (one). Of the six patients treated, all underwent transvenous catheterization and received urokinase infusions of 200,000 to 1,000,000 IU. Three patients underwent superselective catheterization of their straight sinus, and two were treated with mechanical snare maceration of their urokinase-resistant thrombus. One of these underwent both superselective deep venous catheterization and mechanical clot maceration (Case 1, Table 2 ). Some restoration of sinus/deep venous patency was achieved in all patients as confirmed on postprocedural angiographic studies and on MR imaging and MR venography prior to hospital discharge. At dis- charge all of the patients had improved neurologically. Five patients were independent with respect to cognitive and motor function, and two, one of whom required assistance with activities of daily living, had residual hemipareses. Complications that occurred during the hospital stays included aspiration pneumonia (one), cystitis (two), and complicated cystitis with hematuria (one).
Illustrative Cases

Case 5
This 29-year-old man with a known history of nephrotic syndrome and a positive anticardiolipin antibody screen presented after several months of headaches. Just prior to admission, his persistent left frontal headaches changed to a frontoorbital location. This was followed by acute onset of nausea, vomiting, visual changes, dizziness, and gait instability. After treatment with sumatriptan succinate he became increasingly lethargic and somnolent. On neurological examination he was noted to have a left-sided homonymous hemianopsia and marked left-sided extinction. A head CT scan revealed a right temporal lobe hemorrhagic infarction and a sinus thrombosis that were confirmed on MR imaging (Fig. 2) . Despite medical management, including steroid administration, heparin anticoagulation therapy, and volume expansion, his neurological status continued to deteriorate. On Day 3 of his hospitalization he underwent angiographic evaluation. Cerebral arteriography demonstrated thrombosis of the left internal jugular vein, left sigmoid sinus, and bilateral transverse sinuses. Transvenous microcatheterization of the left internal jugular vein was performed, followed by infusion of 200,000 IU of urokinase directly into the thrombus. Systematic advancement of the microcatheter with concomitant urokinase infusion resulted in progressive lysis of the intraluminal clot and reopening of the sinuses.
Results of the patient's neurological examination improved immediately after the endovascular therapy, although bilateral abducent nerve palsies persisted. He continued to receive intravenous heparin anticoagulation therapy, which was converted to a course of oral warfarin prior to discharge from the hospital. Twelve months after discharge he remains neurologically intact except for bilateral partial sixth cranial nerve palsies. (Fig. 3) . Because of these findings and her rapidly deteriorating neurological condition, the patient underwent emergency diagnostic arteriography followed by transvenous catheterization. Urokinase was initially infused into the left transverse sinus. After partial patency was achieved, superselective catheterization of the proximal straight sinus was performed with additional infusion of urokinase (Fig. 4) . After a total infusion of 1,000,000 IU of urokinase over 4 hours, patency of the deep venous system and transverse sinuses was achieved. Her mental status improved immediately postprocedure. She continued to receive systemic anticoagulation therapy, which was subsequently converted to oral warfarin. By the time of discharge, she displayed markedly improved strength in her left side, was ambulatory with assistance, and had normal speech. Five months after discharge her MR venographic study demonstrated open sinuses (Fig. 3) , and she was living independently.
Case 1
This 35-year-old woman with a known history of ulcerative colitis presented with a 4-day history of bifrontal headache followed by the acute onset of right-sided hemiparesis with hypesthesia, vomiting, and diplopia. Brain MR imaging revealed thrombosis of her superior sagittal sinus (SSS). She was treated with intravenously administered heparin anticoagulation therapy along with hydration and steroid medication, and her neurological examination results returned to normal. Her anticoagulation therapy was converted to oral warfarin and she was discharged home.
Four weeks after discharge, her oral warfarin therapy was temporarily discontinued for performance of a colonoscopy procedure. Two days later she returned to the hospital with headache, nausea, and vomiting. Magnetic resonance imaging analysis revealed a thrombosed poste- rior one third of the SSS, bilateral transverse sinuses, and straight sinus, and limited filling of her deep venous system. Right femoral artery catheterization was performed to allow diagnostic arteriography followed by ipsilateral transvenous catheterization (Fig. 5) . The transvenous microcatheter was advanced to the level of the torcular, into which 200,000 IU of urokinase was infused. After reestablishing partial patency, the catheter was systematically advanced into the SSS, straight sinus, and the left transverse sinus. Due to the presence of a clot in the SSS that was refractory to treatment with thrombolytic agents, mechanical snare maceration of the thrombus was used to open the venous system (Fig. 5) . After a total infusion of 1,000,000 IU of urokinase and mechanical clot maceration, contrast filling of the SSS, transverse sinuses, and deep venous system was evident. There were no neurological complications.
The patient experienced immediate resolution of her symptoms, and she continued to receive systemic anticoagulation therapy. After conversion to oral warfarin, she was discharged home symptom free and with normal neurological findings. At her 10-month follow-up examination she showed no evidence of recurrent thrombosis.
Discussion
Cerebral venous thrombosis is uncommon and has an unpredictable clinical course. In this report we describe six patients who improved after multimodality endovascular therapy of their cerebral venous thrombosis. Because intraparenchymal changes can be seen on presentation with venous occlusion on MR imaging, rapid diagnosis is essential and immediate treatment is imperative in patients with progressive neurological deterioration. 34, 41 Although earlier reports have indicated improved outcome after systemic anticoagulation, 6 it was not until 1991 that a prospective randomized clinical trial showed 80% complete recovery with no deaths in the group receiving anticoagulation therapy compared with a 10% complete recovery and 30% dead in the group receiving placebo. 16 Subsequent reports have not shown that the use of systemic anticoagulation therapy consistently leads to successful outcomes. 9, 31 Investigators have attributed this unpredictability to a variety of factors including the cause of procoagulant activity (Behçet's disease, puerperium), rate of thrombus development, and involvement of the deep venous structures. 8, 9, 11, 26 Because of the high variability and unpredictability of systemic anticoagulation therapy 6, 16 and the relative risks of operative thrombectomy, 33, 35 clinicians have explored a minimally invasive thrombolytic approach in which local and systemic fibrinolysis are used. 2, 4, 14, 20, [22] [23] [24] 26, 30, 36, 37, 40 To avoid perfusing ischemic or infarcted brain with fibrinolytic agents via systemic administration, 14, 20 methods of direct infusion of thrombolytic agents into the thrombosed vessel were considered. Higashida, et al., 22 and Scott, et al., 33 infused urokinase directly into the SSS via the anterior fontanel and a midline frontal craniectomy, respectively. Although Scott, et al., considered intervention via femoral vein catheterization, they had less confidence in the angiographic techniques available at that time. Subsequently, Barnwell and colleagues 3 selectively lysed dural sinus thrombi with urokinase via a transjugular route in three patients with progressive neurological deterioration. With the improvement in microcatheter systems and interventional techniques, rapid access to the dural sinuses via a transfemoral route has become the established method for administering anticoagulation therapy. The selective delivery of fibrinolytic agents to the thrombosed dural sinus, resulting in radiographically confirmed patency of the vessel, appears to correlate with a more rapid and predictable improvement in symptoms. [23] [24] [25] [26] 36 In the larger series of patients who were endovascularly treated, Smith and colleagues 36 demonstrated sinus patency in all cases and attenuation or improvement of neurological deficits in six of seven patients treated. Horowitz, et al., 24 showed sinus patency in 11 of 12 patients, and good to excellent clinical outcome in 10 (91%) of 11.
Recent advances in imaging techniques have allowed earlier diagnosis of cerebral venous thrombosis and have helped identify a subset of patients with a predictably worse outcome, namely those with associated deep venous thrombosis. 7, 37 Much of the earlier work on intracranial venous thrombosis centered around dural sinus thrombosis, but more recent observations indicate that thrombus extending beyond the superficial sinuses (deep cerebral veins or cortical veins) is an independent predictor of poor outcome. 4, 7, 9, 23, 33, 37 Several investigators have demonstrated that occlusion of only the SSS does not cause a reduction in the regional parenchymal blood flow, but that occlusion of the ascending veins must exist for adverse effects on regional parenchymal blood flow to occur. 18, 28 The attenuation of the rapid neurological deterioration in the patient in Case 4 after treatment with superselective catheterization of her straight sinus and thrombolysis coincides with previous observations. 23, 37 Although this patient may have recovered with systemic heparinization alone, the temporal relationship between her rapid neurological deterioration and subsequent improvement after thrombolysis suggests that direct thrombolytic therapy to her deep cerebral venous system facilitated her excellent outcome.
The intermittent failure of fibrinolytic agents to dissolve venous thrombus adequately and the usefulness of concomitant mechanical thrombus disruption has been recognized in a variety of extracranial clinical circumstances. Combined mechanical and pharmacological (pharmacomechanical) thrombolysis of thrombosed dialysis grafts has demonstrated a high degree of success with limited iatrogenic complications. 5, 13, 39, 42 Furthermore, mechanical thrombolysis in combination with fibrinolytic agent administration has resulted in rapid improvements in hemodynamics and blood oxygenation in patients with massive pulmonary embolisms. 17 Other investigators have recognized that intracerebral mechanical clot fragmentation with the microinfusion catheter has increased surface area of the intracerebral thrombus and made it more amenable to pharmacological treatment. 2, 3, 10, 24, 26 Successful mechanical disruption of intracranial venous thrombus by using the microcatheter and its guidewire has been reported. 24, 26 However, in our series the microsnare showed significant advantages over the guidewire and microcatheter in macerating the thrombus. Unlike the guidewire and microcatheter, the increased surface area resulting from the snare's loop con-figuration and its ability to be repeatedly opened and closed allows for rapid and efficient clot fragmentation, whereas its flexibility and easy maneuverability do not increase its potential for vessel injury as compared with the microcatheter alone. 2, 40 Finally, the age of the thrombus has been implicated in its response to pharmacological thrombolysis. 3, 24 In the patient in Case 1, this may have been a significant factor because thrombolysis was performed 4 weeks after the initial symptoms. Mechanical clot maceration may help reduce iatrogenic complications by increasing the thrombus surface area exposed to pharmacological treatment, thus resulting in lower doses of fibrinolytic agents and a shorter procedure time. 2 In a review of all reported cases of endovascular treatment of cerebral venous thrombosis in the English literature, we found consistent clinical improvement and an overall improvement rate of 93% after compilation of the cases into a single group (Table 3) . Adding the patients from the present report to the group increases the improvement rate to 94% with only a 2% mortality rate. This rate of improvement appears to be uniformly more reproducible with endovascular thrombolysis than with systemic anticoagulation. One theoretical pitfall associated with endovascular thrombolytic therapy may arise in patients with concomitant intraparenchymal hemorrhages, in whom heparin treatment has been shown to be contraindicated. 16 However, in several series, including ours, there have been no significant intracerebral hemorrhagic complications in this select group of patients after they were treated with endovascular thrombolytic agents. 24, 32, 37 This is thought to be due to the relatively rapid metabolism of the thrombolytic agent and, thus, the relatively low arterial concentration of the fibrinolytic agent. Furthermore, as described previously, mechanical maceration of the thrombus reduces the total volume of thrombolytic agent required for adequate thrombolysis. Unlike heparin anticoagulation therapy, thrombolytic agents can promptly accomplish two therapeutic goals: 1) attenuation of thrombus progression; and 2) restoration of venous flow. Furthermore, because of the flexible catheters and the rapid systemic inactivation of urokinase, the systemic and intracranial complications appear to be no more than those of systemic anticoagulation in the acute period.
Conclusions
Therapy for cerebral venous thrombosis remains controversial, and there is no clear consensus on an approach that optimizes patient outcome. There has been only one randomized prospective clinical study 16 evaluating any treatment option for this disease, and further assessment of the potential role and benefit of aggressive and early endovascular therapy for cerebral venous thrombosis must be pursued. However, given the data presented in our study, endovascular thrombolysis for both dural sinus and deep cerebral veins appears to have the most obvious benefits in the setting of a rapid and progressive neurological deterioration. The results in this group of patients support the use of an interventional neuroradiological approach to promptly restore cerebral venous outflow. Advances in endovascular techniques capable of superselective fibrinolytic and mechanical thrombolysis, including microcatheter systems and mechanical snares, have extended the therapeutic boundaries for this previously unpredictable and potentially catastrophic disease. 
